FITC Plus Anti-Human CD39/ENTPD1 Rabbit Recombinant Antibody

CD39/ENTPD1 Uni-rAbTM Recombinant Antibody for FC
Cat No. FITC-98102

Print datasheet

CloneNo. 241292G7

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

FC

ENTPD1, EC:3.6.1.5, CD39, ATP-DPH, ATPDase

Formulation:  PBS and Azide
PBS and Azide
Size: 

-/ -


经过测试的应用

Positive FC detected inhuman PBMCs

推荐稀释比

ApplicationDilution
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood.
Sample-dependent, Check data in validation data gallery.

产品信息

FITC-98102 targets CD39/ENTPD1 in FC applications and shows reactivity with human samples.

Tested Applications FC Application Description
Tested Reactivity human
Immunogen Recombinant Protein 种属同源性预测
Host / Isotype Rabbit / IgG
Class Recombinant
Type Antibody
Full Name ectonucleoside triphosphate diphosphohydrolase 1
Synonyms ENTPD1, EC:3.6.1.5, CD39, ATP-DPH, ATPDase
Calculated Molecular Weight 58 kDa
GenBank Accession NumberBC047664
Gene Symbol CD39
Gene ID (NCBI) 953
Conjugate FITC Plus Fluorescent Dye
Excitation/Emission Maxima Wavelengths495 nm / 524 nm
Form Liquid
Purification MethodProtein A purification
UNIPROT IDP49961
Storage Buffer PBS with 0.09% sodium azide and 0.5% BSA.
Storage ConditionsStore at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

背景介绍

ENTPD1 (Ectonucleoside triphosphate diphosphohydrolase 1) is also named CD39, NTPDase 1, and Ecto-ATPDase 1 and belongs to the GDA1/CD39 NTPase family. In the nervous system, it can hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. It is a noncovalent tetrameric protein and detergent inhibition of enzymatic activity is caused by dissociation of ectoapyrase tetramers into monomers (PMID: 9733785 ).

实验方案

Product Specific Protocols
FC protocol for FITC Plus CD39/ENTPD1 antibody FITC-98102Download protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...